AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Public ClinicalTrials.gov record NCT00219557. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A RANDOMIZED PHASE 2 STUDY OF THE ANTI-ANGIOGENESIS AGENT AG-013736 IN COMBINATION WITH GEMCITABINE IN PATIENTS WITH CHEMOTHERAPY-NAIVE ADVANCED PANCREATIC CANCER PRECEDED BY A PHASE 1 PORTION
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study being conducted at multiple centers in the United States, Europe and Canada. Patients having pancreatic cancer that is locally advanced or that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have not had any prior systemic treatment for advanced disease. The purpose of the study is to test whether the angiogenesis inhibitor Axitinib \[AG-013736\] in combination with gemcitabine is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall survival.
Study identification
- NCT ID
- NCT00219557
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2005
- Primary completion
- Mar 13, 2008
- Completion
- Mar 13, 2008
- Last update posted
- May 13, 2019
2005 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 8
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| East Bay Medical Oncology/Hematology Medical Associates Inc. | Antioch | California | 94509 | — |
| Alta Bates Comprehensive Cancer Center | Berkeley | California | 94704 | — |
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| East Bay Medical Oncology/Hematology Medical Associates, Inc. | Concord | California | 94520 | — |
| Hematology Oncology, P.C. | Stamford | Connecticut | 06902-3628 | — |
| Jackson Memorial Hospital & Clinics | Miami | Florida | 33136 | — |
| University of Miami Hospital & clinics | Miami | Florida | 33136 | — |
| H Lee Moffitt Cancer Center & Research Institute | Tampa | Florida | 33612-9497 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Biddeford | Maine | 04005 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Brunswick | Maine | 04011 | — |
| Maine Center for Cancer Medicine and Blood Disorders | Scarborough | Maine | 04074 | — |
| Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research | St Louis | Missouri | 63141 | — |
| Arch Medical Services, Inc. d/b/a The Center for Cancer Care and Research | Washington | Missouri | 63090 | — |
| Southeast Nebraska Cancer Center, Southeast Nebraska Hematology and Oncology Consultants, P.C. | Lincoln | Nebraska | 68510 | — |
| Piedmont Hematology Oncology Association | Winston-Salem | North Carolina | 27103 | — |
| Piedmont Hematology Oncology Associates | Winston-Salem | North Carolina | 27292 | — |
| University of Wisconsin Hospital and Clinics | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00219557, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2019 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00219557 live on ClinicalTrials.gov.